Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.
Zacks Investment Research on MSN
Bristol Myers Squibb Company (BMY) is attracting investor attention: Here is what you should know
Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s ...
Most Undervalued Stocks to Invest In. On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic ...
Buy Bristol Myers Squibb (BMY) on the dip: low 8.7x forward P/E, 4.6% yield, 9% sales growth and key H2 2026 readouts.
The latest medicines from Bristol Myers Squibb (BMY +0.47%) were the driving force behind the company's considerable share price gain on Thursday. The pharmaceutical company's fir ...
Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. The drug, casdatifan, will be ...
Bristol Myers Squibb—a biopharmaceutical company—is considering building a roughly 600,000 square-foot manufacturing facility in McCord Development's Generation Park, according to a May 16 tax ...
19don MSN
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results